Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer
P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effector-related toxicities were observed in some patients, a novel iCasp9 safety switch was largely effective in mitigating toxicity.
Authors
- Rosa Nadal (ORCID: https://orcid.org/0000-0002-6836-9731)
- Michael Thomas Schweizer (ORCID: https://orcid.org/0000-0002-5510-0661)
- Patrick C. Lee (ORCID: https://orcid.org/0000-0001-9291-6179)
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-06-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0959
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00